|
Case Studies for CPCA Scoring
|
|
18
|
4062
|
September 30, 2024
|
|
🖩 CPCA Calculation Tool (excel-based) -Updated
|
|
87
|
10809
|
September 27, 2024
|
|
Multiple Secondary Amine Groups in the Same Molecule
|
|
2
|
211
|
September 26, 2024
|
|
Royal Australian Chemical Institute
|
|
0
|
79
|
September 26, 2024
|
|
New paper - Use of molar, instead of weight-based, safety limits
|
|
17
|
2719
|
September 25, 2024
|
|
57th Congress of the European Societies of Toxicology (EUROTOX 2023)
|
|
2
|
686
|
September 24, 2024
|
|
Cleaning Validation Swab Sampling for Nitrosamine Impurities
|
|
1
|
177
|
September 24, 2024
|
|
Residual limits of nitrosamine impurities in cleaning validation
|
|
0
|
130
|
September 24, 2024
|
|
Low-concentration nitrosamine impurity sample detection method
|
|
0
|
106
|
September 24, 2024
|
|
Presencia de Nitrosaminas en Materiales de empaque. Presence of Nitrosamines in packaging materials
|
|
4
|
306
|
September 23, 2024
|
|
Facing Up to the New Nemesis of Pharma: Nitrosamines What’s going on with nitrosamines in pharmaceutical products? Naiffer Romero, Principal Scientist at the US Pharmacopeia walks us through frequently asked questions
|
|
0
|
183
|
September 23, 2024
|
|
Primeros pasos para evaluar nitrosaminas en medicamentos
|
|
5
|
179
|
September 23, 2024
|
|
🙋♂️ Citizen Petition to FDA on Sitagliptin
|
|
21
|
3475
|
June 7, 2024
|
|
Dietary exposure assessment for volatile N-nitrosamines from food and beverages for the U.S. population -Pub
|
|
0
|
110
|
September 18, 2024
|
|
9th Impurities: Genotoxic, Nitrosamine, & Beyond Summit
|
|
0
|
336
|
September 18, 2024
|
|
Exposure to Valsartan Products Containing Nitrosamine Impurities in the United States, Canada, and Denmark
|
|
0
|
85
|
September 18, 2024
|
|
Escaping the cohort of concern: in vitro experimental evidence supports non-mutagenicity of N-nitroso-hydrochlorothiazide -Pub
|
|
1
|
208
|
September 18, 2024
|
|
PMDA-USP Workshop - Nitrosamines Track
|
|
2
|
493
|
September 17, 2024
|
|
Metformin drugs under simulated gastric conditions can generate high nitrite-dependent levels of N-nitrosodimethylamine
|
|
5
|
942
|
September 17, 2024
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
1
|
239
|
September 17, 2024
|
|
N-Nitroso Carbidopa
|
|
2
|
272
|
September 12, 2024
|
|
Can API with amide should considered a potential candidate for forming nitrosamine impurity
|
|
5
|
286
|
September 12, 2024
|
|
How to calculate limits for Di nitrosamine compounds in API, eg: 1,4-Di-ntrosopirrazine
|
|
4
|
224
|
September 11, 2024
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
0
|
195
|
September 10, 2024
|
|
Novartis pauses some trials of cancer drug Kisqali to fix manufacturing
|
|
13
|
1831
|
September 9, 2024
|
|
NDMA testing in metformin
|
|
5
|
205
|
September 9, 2024
|
|
Potential Topic for an event concerning obtaining the right level of Nitrosamine Risk Assessment information from your CMOs
|
|
22
|
1621
|
September 5, 2024
|
|
Vildaglibtin and Metformin in combinationy
|
|
1
|
529
|
October 17, 2023
|
|
EMA Q&A Appendix 1 is updated Sept 4, 2024
|
|
18
|
1586
|
September 6, 2024
|
|
Negative EAT could probably result in ICH Q3B?
|
|
10
|
337
|
September 5, 2024
|